Primary Biliary Cholangitis clinical trials at UC Davis
6 research studies open to eligible people
A Study Evaluating an Investigational Medicine for Treating PBC Itch (The GLISTEN Trial)
“Volunteering for the GLISTEN trial could bring much-needed medical progress in PBC itch!”
open to eligible people ages 18-80
This is a 2-part study in PBC participants with cholestatic pruritus and will evaluate the efficacy, safety and impact on health-related quality of life of linerixibat compared with placebo.
Sacramento, California and other locations
A Study of Investigational Seladelpar in Primary Biliary Cholangitis (PBC)
“Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!”
open to eligible people ages 18-75
To evaluate the treatment effect of seladelpar on composite biochemical improvement in cholestasis markers based on ALP and total bilirubin and to evaluate the safety of seladelpar over 12 months of treatment compared to placebo
Sacramento, California and other locations
A Study of Seladelpar in Patients with Primary Biliary Cholangitis (PBC) and Abnormal Liver Function
“Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!”
open to eligible people ages 18-80
The Effect of Hepatic Impairment on The Pharmacokinetics of Seladelpar: An Open-Label Study Following Oral Dosing of Seladelpar to Subjects with Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)
Sacramento, California and other locations
If you’re living with Primary Biliary Cholangitis, learn about our study of a novel combination therapy
“Primary Biliary Cholangitis may be rare. But we’re working together.”
open to eligible people ages 18 years and up
Study to determine the effect of the investigational drug bezafibrate (BZF) alone and in combination with the investigational drug obeticholic acid (also known as OCA) in patients with Primary Biliary Cholangitis (also known as PBC).
Sacramento, California and other locations
Phase 3 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cirrhosis
open to eligible people ages 18 years and up
Primary Biliary Cholangitis (PBC) is a serious, life-threatening, bile acid related liver disease of unknown cause. Without treatment, it frequently progresses to liver fibrosis and eventual cirrhosis requiring liver transplantation or resulting in death. The investigational drug, Obeticholic Acid (OCA) is a modified bile acid and FXR agonist that is derived from the primary human bile acid chenodeoxycholic acid. The key mechanisms of action of OCA, including its choleretic, anti-inflammatory, and anti-fibrotic properties, underlie its hepatoprotective effects and result in attenuation of injury and improved liver function in a cholestatic liver disease such as PBC. The study will assess the effect of OCA compared to placebo, combined with stable standard care, on clinical outcomes in PBC participants.
Sacramento, California and other locations
Study to Evaluate a Potential New Treatment in Primary Biliary Cholangitis
“Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!”
open to eligible people ages 18-75
This study is a Phase 2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-104. The study consists of a 120 day primary study followed by a 20 month long-term safety and durability of response follow-up period.
Sacramento, California and other locations
Our lead scientists for Primary Biliary Cholangitis research studies include Christopher Bowlus, MD.